Professional Documents
Culture Documents
Cannabinoids
Marijuana Smoking vs
for Glaucoma Therapy
Keith Green,
Objective: To discuss the clinical effects, including toxi-
cological data, of marijuana and its many constituent com-
pounds
is
the
in
the
able
of these herbal preparations
and the parallel development of specific
medications that were more potent and tar-
geted toward specific symptoms. This philo-
sophical alteration in medical therapy re-
flected changes that occurred in all branches
of medicine.’ Only in the latter part of this
century has marijuana been used as a plea-
sure-inducing substance during liberaliza-
tion of ethics and social behavior in many
cultures.“-‘” After tobacco, alcohol. and caf-
feine, it is probably the most widely used
drug in society.
See
P
1998 at New
of the ocu-
lar and toxic effects of mari-
juana
REVIEWS
due to the
side no
effects. Smoking of
marijuana
of
further pursuit. Among
School
adverse
oc-
cur in greater concentration than
in to-
bacco
is little but
anecdotal material on which to rely, but
in the area of glaucoma, there exists a sub-
stantial literature.
MEDICAL EFFECTS
A number of health hazards of marijuana
have been identified, but some are diffi-
cult to document
tobacco
smoke.‘“-” The latter products.
In many areas of
Acute
effects are increased pulse rate, orthostatic
hypotension. euphoria. and conjunctival
Long-rerm peremia.
clinical effects in hu-
mans include respirator), hormonal, and
material for
chemicals. some
reduction of
Seven of 11 patients in 1 study showed a
reduction in IOP of abour 30% after smoking 2% mari-
juana cigarettes.
More quantities of oral drug or mari-
juana were needed compared with inhaled drug, pre-
sumably due to the poorer absorption by the former route.
or mari-
juana (“brownies”) causes conjunctival
intravenous in-
jection of cannabinoids, or ingestion of
after
ing level,
The major difficulty with marijuana smok-
ing was to separate the reduction in IOP and the eu-
phoric effect. These findings confirmed the physiological
and pharmacological effects found in experimental ani-
mals after intravenous drug
and de-
creased lacrimation.
This is
chronic
about
after inhalation of 2%
(range,
in 60% to
and
when
to
The
disease.” No in-
dication has been obtained or reported that those highly
limited number of persons who consume marijuana ciga-
rettes as a compassionate investigational new drug have
shown any maintenance of visual function or visual fields
or stabilization of optic disappearance.
Since marijuana reduces IOP for 3 to 4 hours, after
which the IOP returns to baseline, control of IOP at a
significantly lowered value, including maintenance of IOP
at a
minimal low value, requires a marijuana ciga-
rette to be smoked 8 or
a day (by those persons
in whom
ies to
high. The
IOP is the only readily measurable parameter that one can
use as an index of POAG and is still the major indicator
of what is essentially a
soluble esters of a
and keep
actually
salt of a
needed to
and toxic
in
to at least 2920 and
many as 3650 marijuana ciga-
rettes consumed per year.
It is difficult to imagine any-
one consuming that much
reduction.@
Glaucoma treatment requires a round-the-clock re-
duction in IOP, and treatments are evaluated as success-
ful if this level of activity is achieved without progres-
sion of
an oral form of
and being a
The
binoids in causing an
high
ratio of IOP reduction to euphoric effects. Such chemi-
cals would eliminate any potential abuse problems while
providing drugs that would reduce IOP
unique inter-
action with receptors or other membrane components that
could be additive to other currently available glaucoma
medications.
ular meshwork
in several
ways from the conclusions reached
review ization. A
of medicinal appli-
cations that evaluated the effect of
and
marijuana on a broad spectrum of medical problems
indicated that THC may have a role in treating nausea
associated
and in appetite
stimulation. Other uses of either material
not
supported.”
effects.
Because they are readily characterized from a
and
cancer
such as
or
21.
22.
23.
24.
25.
26
11.
12.
13.
14.
15.
16.
17.
18.
19.
3
4
5
6
7
8
9.
Solowij N, Michie PT, Fox AM. Differential impairments of selective attention due
to frequency and duration of cannabis use.
tute of
AC. Determination
and characterization of a cannabinoid receptor in rat brain.
Press. In press.
Agurell S, Dewey WL, Willette RE. eds. The Cannabinoids: Chemical, Pharma-
cologic and Therapeutic Aspects. Orlando.
Chronic Tashkin
ef-
fects of heavy marihuana smokrng on pulmonary function
Thomas Munro
KL, Abu-Shaar M. Molecular characterization of a peripheral
receptor for cannabinoids. Nature.
research in ophthalmol-
ogy. In: Leopold
Academic Press
Green
Green
1984.
Graham
1976.
Dewey WL. Cannabinoid pharmacology.
Rosenkrantz H.
users.
In: Braude MC. Szara S. eds. The
of Marihuana. New York, NY:
Raven Press:
Toxi-
cology. New York. NY: Raven Press;
eds. Cur-
rent
Mechoulam
Bibliography.
and personality.
Kalant
McDonald
History of
in
and
Shapiro
Cannabis and
Research. Orlando.
Sons
Washington. DC.
Gen Psycho/.
Urbanek
Academic Press
Turner CE.
Academic Press
very long-term
Psychiatry.
Academy of Sciences.
Consequences of
JA,
substances on
1982:
51
52
53
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47
48
as a po-
tential glaucoma agent. Glaucoma.
JM. Topi-
cal
Jones RT.
MC. Pupil size af-
ter use of marijuana and alcohol. Am J
glaucoma. II.
the effect of
Aca-
demic Press
Chemical, Pharmaco-
logic and Therapeutic
agonrsts of
the
WW, Jiminez-Antillon CF. Perez JM, Zeskind JA. Marihuana and vision
after ten years’ use in Costa Rica.
pressure,
Green K, Bowman
In: Braude MC, Szara S. eds. The Pharmacology of Marihuana. New York, NY:
Raven Press:
Green K. Symonds CM, Oliver NW, Elijah RD. Intraocular pressure following
Eye
DA, Harland EC, Bedford JA, Murphy JC, El-Sohly MA. Can-
nabinoids in glaucoma, Ill: the effects of different cannabinoids on
binoids: Chemical.
Antiglaucoma Howes
effects of topically and orally administered cannabinoids.
In: Agurell S, Dewey WL, Willette RE, eds.
Pooe
use
Mechoulam R.
Aminoalkylindole ana-
logs:
fxp Ther. 1992:263:1118-l 126.
Lynn AB, Herkenham M. Localization of cannabmoid receptors and
rable
mice.
Perez-Reyes M, Wagner
Brown B, Adams
effects of
11
anandamide. a
E. Mechoulam
CW,
college students,
WA,
of psychotropic activity.
Taha
receptor.
cannabinoid binding
Exp
of
Ungerleider JT.
Eye
Petrus
The
et al.
Effect of
receptor.
Ward SJ,
constituent. Eur J
JJ. Lander
Med Chem.
Tne
Orlando,
1996275
Balster
GH. Mechoulam t?
on intraocular pressure of
Stapleton SS,
a putative endogenous
et al.
Eye
derivatives on
TE,
Martin
AL,
effects of
Press
1990:29:161-l 65.
DA.
SS. Effect of
eds. The
rabbit.
1981:
55. Green K, Bigger JF, Kim
56. Green
57.
59. Green
60.
61.
1997:90:167-l 72.
66. Allen T. Tetrahydrocannabinol and chemotherapy [letter].
68.
64 Poster
XVII: a
review of the natural constituents.
Cultivation, extraction
and analysis of Cannabis
in humans.
oncology.
M, Aviv
JC,
Green K.
Roth M.
RE,
Friedman
of topically
JS.
Russell RN,
et al.
JR,
Nat Prod.
Ann
MW, Turner
JS.
SM. Topical
Reference:
1%
of
Ann
Med. 1976;
and
C. Rotation of
in
70. Green K, Kim K. Acute dose response of intraocular pressure to topical and oral
cannabinoids.
71. Mechoulam
072.
72. Newell
74.
76. Pate
77. Pate
75. Sugrue
A, et al. Effects of topical anandamides on intraocular
pressure in normotensive rabbits. Life Sci 1996:58:1849-l 860.
78. Hodges LC. Reggio PH. Green K. Evidence against
79.
353-357.
80. Wall ME. Brine DR.
Press. In press.
82. Voth EA. Schwartz RH. Medicinal applications of
rye.
receptor involve-
ment in intraocular pressure- effects of
Jarvinen
Jarvinen
Stark
Lander N,
The
A,
Med.
M. Metabolism of cannabinoids
Med.
and
in
Totawa. NJ:
1986:
Res.
So.